CTLA4 and melanoma: The Food and Drug Administration’s 2011 approval of ipilimumab, an anti-CTLA-4 antibody, marked a milestone for advanced melanoma patients, demonstrating extended survival in a Phase III trial (Hodi et al., 2010; Robert et al., 2011).